The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease

På svenska

Author

Summary, in English

Background: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia. Methods: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias. Results: We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias. Conclusions: Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease.

Publishing year

2015

Language

English

Publication/Series

BMC Neurology

Volume

15

Document type

Journal article review

Publisher

BioMed Central (BMC)

Topic

  • Neurology

Keywords

  • Anti-phosphorylcholine
  • Alzheimer's disease
  • Dementia
  • Biomarker

Status

Published

Research group

  • Biomarkers in Brain Disease
  • Clinical Memory Research

ISBN/ISSN/Other

  • ISSN: 1471-2377